tirzepatide tucson Weight Loss Clinic | GLP-1 & Medical Weight Loss semaglutide and tirzepatide in tucson

Nivaan Health selected tirzepatide for its dual GIP/GLP-1 receptor mechanism, which clinical data associates with fewer gastrointestinal side effects and greater weight reduction compared to single-receptor GLP-1 agonists

protocol before prescribing medications or recommending strength exercises

The SmPC for Wegovy lists gastrointestinal side effects as most common (nausea, diarrhoea, vomiting, constipation), but does not specifically highlight panic attacks as a recognised adverse reaction

Adults ages 18 and older may qualify for coverage with a prior authorization by meeting either of the two conditions below: You have already used Wegovy for at least three months at a stable maintenance dose and lost at least 5% of your baseline body weight (or maintained a 5% weight loss)

Stay Lovely, Erin